Using this system, we performed parallelized screening for inflammation‐initiating immune cells by i) individually loading distinct immune cell populations into the basal compartments, ii) applying a clinically relevant level of LPS on the apical side of the IEB model,[39] and iii) selectively adding interferon‐γ (IFN‐γ) to selected basal compartments to trigger inflammatory conditions.[40, 41] We then demonstrated the potential of our system for drug testing by treating inflamed IEB model units with Infliximab – one of the most widely used TNF blockers for treating IBD. This evidence concerns the gene IFNG and inflammatory bowel disease.